Anastrozole
Product Images NDC 54868-6130

6 FDA label images from Physicians Total Care, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 54868-6130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Of Chemical Structure (Chemical Structure)

Image Of Chemical Structure (Chemical Structure)
Chemical structure diagram of the active ingredient Anastrozole, showing its characteristic nitrogen-containing ring and cyano-substituted aromatic groups.*
FDA Label Image

Image Of Figure 1 (Figure 1)

Image Of Figure 1 (Figure 1)
Kaplan Meier survival curve chart showing disease-free survival over time (months) for patients randomized to Anastrozole tablets or Tamoxifen monotherapy in the ATAC trial. The y-axis represents the proportion alive and disease-free, and the x-axis shows months of disease-free survival, with patient risk numbers indicated below.*
FDA Label Image

Image Of Figure 2 (Figure 2)

Image Of Figure 2 (Figure 2)
A line graph illustrating disease-free survival over months for patients with hormone receptor-positive subpopulation randomized to either Anastrozole or Tamoxifen in the ATAC Trial. The graph plots proportion alive and disease-free on the vertical axis against time in months on the horizontal axis, with two lines representing Anastrozole and Tamoxifen treatments and patient numbers at risk provided below the timeline.*
FDA Label Image

Image Of Figure 3 (Figure 3)

Image Of Figure 3 (Figure 3)
Kaplan-Meier plot illustrating the probability of time to disease progression in months for patients in Trial 0030. The graph compares two randomized treatments: Anastrozole and Tamoxifen, showing the proportion of patients not progressing over time with corresponding patient numbers at risk displayed below the x-axis.*
FDA Label Image

Image Of Figure 4 (Figure 4)

Image Of Figure 4 (Figure 4)
A Kaplan-Meier plot showing the probability of time to progression in months for patients in Trial 0027, comparing Anastrozole and Tamoxifen treatments. The y-axis represents the proportion not progressing, and the x-axis shows time in months, with data points and risk numbers indicated for each treatment over a 42-month period.*
FDA Label Image

Image Of Package Label (Package Label)

Image Of Package Label (Package Label)
Label for Anastrozole 1 mg tablets showing the distributor as Physicians Total Care, Inc. from Tulsa, OK. The label includes the product NDC 54868-6130-0, lot number 0000, and expiration date 01/60. The manufacturer is listed as Novco Pharma Limited in India. A barcode and numeric code are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.